These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 8947970)

  • 1. Viral infectivity of albumin and plasma protein fraction.
    Erstad BL
    Pharmacotherapy; 1996; 16(6):996-1001. PubMed ID: 8947970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification.
    Azzi A; Maggi F; Zakrzewska K; Menconi MC; Di Pietro N; Salotti V; Farina C; Andreoli E; Fiorentino B; Angelini C; Corcioli F; Bendinelli M
    Transfusion; 2006 Jul; 46(7):1162-7. PubMed ID: 16836563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral safety of recombinant factor IX.
    Adamson S; Charlebois T; O'Connell B; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
    Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
    Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond HIV, HBV and HCV--how to deal with other viruses?
    Minor PD
    Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of fibrin sealants.
    Joch C
    Cardiovasc Surg; 2003 Aug; 11 Suppl 1():23-8. PubMed ID: 12869985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A probabilistic model for analyzing viral risks of plasma-derived medicinal products.
    Janssen MP; Over J; van der Poel CL; Cuijpers HT; van Hout BA
    Transfusion; 2008 Jan; 48(1):153-62. PubMed ID: 17894786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the risk of infection from plasma products: specific preventative strategies.
    Burnouf T; Radosevich M
    Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products.
    Welch J; Bienek C; Gomperts E; Simmonds P
    Transfusion; 2006 Nov; 46(11):1951-8. PubMed ID: 17076851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral safety of clotting factor concentrates.
    Fricke WA; Lamb MA
    Semin Thromb Hemost; 1993; 19(1):54-61. PubMed ID: 8456324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasma fractionation. Progress, problems and perspectives].
    Burnouf T
    Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral validation of the manufacturing process of high purity albumin from placentas.
    Grandgeorge M; Véron JL
    Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of needs for plasma for fractionation in Europe.
    Burckhardt JJ
    Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. At what stage should virus inactivation be carried out?
    Dorner F; Barrett PN; Eibl J
    Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective inactivation of a wide range of viruses by pasteurization.
    Gröner A; Broumis C; Fang R; Nowak T; Popp B; Schäfer W; Roth NJ
    Transfusion; 2018 Jan; 58(1):41-51. PubMed ID: 29148053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.